| abstract |
The invention relates to engineered antibodies that specifically bind to integrin receptors, in particular the alpha V integrin receptor subunit. These antibodies contain antigen binding sites (CDRs) of a known mouse integrin antibody, hybrid light chain variable sequences, mutated heavy chain variable sequences (FR), and modified heavy chain constant constants. These new antibodies have improved immunogenic and expression properties and cause excellent activity, both antiangiogenic and antitumor, in humans with monotherapy, but also, and above all, in combination with other agents that inhibit angiogenesis and tumor. |